Outcomes Following Adalimumab Bio-originator to Biosimilar Switch-A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries.
Peter C TaylorYuri Sanchez GonzalezRyan ClarkFreddy FaccinOliver HowellPublished in: Rheumatology and therapy (2023)
Non-medical switching in RA treatment may lead to unforeseen outcomes that should be considered by health decision-makers.
Keyphrases
- healthcare
- rheumatoid arthritis
- public health
- emergency department
- primary care
- case report
- mental health
- type diabetes
- machine learning
- systemic lupus erythematosus
- human health
- health promotion
- ankylosing spondylitis
- insulin resistance
- replacement therapy
- weight loss
- social media
- smoking cessation
- idiopathic pulmonary fibrosis